Anterogen.Co.,Ltd. (KOSDAQ:065660)

South Korea flag South Korea · Delayed Price · Currency is KRW
37,400
+200 (0.54%)
Apr 28, 2026, 3:30 PM KST
80.68%
Market Cap 374.23B
Revenue (ttm) 7.54B
Net Income (ttm) -1.37B
Shares Out 10.01M
EPS (ttm) -138.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,544
Average Volume 40,817
Open 37,000
Previous Close 37,200
Day's Range 36,500 - 37,850
52-Week Range 19,380 - 61,800
Beta 0.02
RSI 42.11
Earnings Date n/a

About Anterogen.Co.,Ltd.

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 065660
Full Company Profile

Financial Performance

In 2025, Anterogen.Co.,Ltd.'s revenue was 7.54 billion, an increase of 8.71% compared to the previous year's 6.93 billion. Losses were -1.37 billion, -40.08% less than in 2024.

Financial Statements

News

There is no news available yet.